Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Scott Algara, Daniel ^a   Mancini Bourgine, Maryline ^a,b   Fontaine, Hélène ^c   Pol, Stanislas ^c   Michel, Marie Louise ^a,b,c  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c Université René Descartes Paris V ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CELL MARKER; DNA VACCINE; HEPATITIS B VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE; LEUKOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INNATE IMMUNITY; MALE; NATURAL KILLER CELL; T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HETEROZYGOTE; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; VIRUS LOAD;

HEPATITIS B VIRUS;

ANTIGENS, CD; CARRIER STATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; VACCINES, DNA; VIRAL LOAD;

EID: 77649282342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008761     Document Type: Article

References (43)

1. Orange JS, Ballas ZK (2006) Natural killer cells in human health and disease. Clin Immunol 118: 1-10.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9: 503-510.
3. Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957-964.
4. Wieland SF, Chisari FV (2005) Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79: 9369-9380.
5. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, et al. (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58: 974-982.
6. Pol S, Michel ML (2006) Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 5: 707-716.
7. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, et al. (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40: 874-882.
8. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, et al. (1999) DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 189: 169-178.
9. Krieg AM (2003) CpG motifs: the active ingredient in bacterial extracts? Nat Med 9: 831-835.
10. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18: 927-974.
11. Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157: 1840-1845.
12. Michel M-L, Davis HL, Schleef M, Mancini M, Tiollais P, et al. (1995) DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci, USA 92: 5307-5311.
13. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, et al. (1996) DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 93: 12496-12501.
14. Loirat D, Lemonnier FA, Michel ML (2000) Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 165: 4748-4755.
15. Davis HL, McCluskie MJ, Gerin JL, Purcell RH (1996) DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A 93: 7213-7218.
16. Rehermann B, Naoumov NV (2007) Immunological techniques in viral hepatitis. J Hepatol 46: 508-520.
17. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24: 4482-4489.
18. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, et al. (2000) Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32: 1117-1124.
19. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L (2008) NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15: 226-233.
20. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, et al. (2004) TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21: 107-119.
21. Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, et al. (2004) CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A 101: 10116-10121.
22. Degli-Esposti MA, Smyth MJ (2005) Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5: 112-124.
23. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19: 65-91.
24. Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101: 6669-6674.
25. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, et al. (2009) Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection. Gastroenterology 137: 1287-300.
26. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, et al. (2009) Natural Killer Cell Functional Dichotomy in Chronic Hepatitis B and Chronic Hepatitis C Virus Infections. Gastroenterology 137: 1151-60.
27. Hokland M, Kuppen PJ (2005) Natural killer cells: from "disturbing" background to central players of immune responses. Mol Immunol 42: 381-383.
28. Chlewicki LK, Velikovsky CA, Balakrishnan V, Mariuzza RA, Kumar V (2008) Molecular basis of the dual functions of 2B4 (CD244). J Immunol 180: 8159-8167.
29. Aguilar P, Mathieu CP, Clerc G, Ethevenot G, Fajraoui M, et al. (2006) Modulation of natural killer (NK) receptors on NK (CD3-/CD56+), T (CD3+/ CD56-) and NKT-like (CD3+/CD56+) cells after heart transplantation. J Heart Lung Transplant 25: 200-205.
30. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, et al. (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204: 667-680.
31. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, et al. (2004) Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173: 6072-6081.
32. Jinushi M, Takehara T, Tatsumi T, Yamaguchi S, Sakamori R, et al. (2007) Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology 120: 73-82.
33. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790.
34. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, et al. (2008) The NKG2D receptor: immunobiology and clinical implications. Immunol Res 40: 18-34.
35. Zhou H, Luo Y, Lo JF, Kaplan CD, Mizutani M, et al. (2005) DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A 102: 10846-10851.
36. Zhou H, Luo Y, Kaplan CD, Kruger JA, Lee SH, et al. (2006) A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood 107: 3251-3257.
37. Chen Y,Wei H, Sun R, Dong Z, Zhang J, et al. (2007) Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 46: 706-715.
38. Poggi A, Costa P, Tomasello E, Moretta L (1998) IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol 28: 1611-1616.
39. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, et al. (1998) Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 161: 3493-3500.
40. Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, et al. (2009) NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses. Blood 113: 6593-6602.
41. Caligiuri MA (2008) Human natural killer cells. Blood 112: 461-469.
42. Virgin HW, Wherry EJ, Ahmed R (2009) Redefining chronic viral infection. Cell 138: 30-50.
43. Chan CJ, Andrews DM, Smyth MJ (2008) Can NK cells be a therapeutic target in human cancer? Eur J Immunol 38: 2964-2968.